On 6 June 2010, orphan designation (EU/3/10/751) was granted by the European Commission to Verius Limited, United Kingdom, for synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA for the prevention of delayed graft function after renal transplantation.
This medicine is now known as teprasiran.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.
The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlands, in August 2019.
In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.
Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA (teprasiran)
Prevention of delayed graft function after renal transplantation
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: